Aurinia settles Teva patent suit, bars generic voclosporin launch until Dec. 7, 2036

Reuters2026/08/19 20:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Aurinia Pharmaceuticals settled patent litigation with Teva over a proposed U.S. generic voclosporin 7.9 mg capsule.
Teva stipulated two Aurinia patents expiring in December 2037 are valid, enforceable, and would be infringed by U.S. sales.
Settlement bars a Teva generic launch before Dec. 7, 2036, subject to defined contingencies.
Any launch also depends on FDA approval for Teva’s abbreviated new drug application.
Separate patent cases continue in New Jersey federal court against other generic challengers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260819509870) on August 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Aurinia settles Teva patent suit, bars generic voclosporin launch until Dec. 7, 2036

You may also like

Crypto prices